-
1
-
-
0027420334
-
Projected neurodegenerative disease mortality in the United States, 1990-2040
-
Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 12(4), 219-228 (1993).
-
(1993)
Neuroepidemiology
, vol.12
, Issue.4
, pp. 219-228
-
-
Lilienfeld, D.E.1
Perl, D.P.2
-
2
-
-
0029937494
-
Epidemiology of Parkinson's disease
-
Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol. Clin. 14(2), 317-335 (1996).
-
(1996)
Neurol. Clin.
, vol.14
, Issue.2
, pp. 317-335
-
-
Tanner, C.M.1
Goldman, S.M.2
-
3
-
-
13844283590
-
Epidemiology of Parkinson's Disease
-
Watts R, Koller W (Eds). McGraw-Hill Medical Publishing, NY, USA
-
Marras C, Tanner C. Epidemiology of Parkinson's Disease. In: Movement Disorders: Neurologic Principles and Practice (Second Edition). Watts R, Koller W (Eds). McGraw-Hill Medical Publishing, NY, USA 177-195 (2004).
-
(2004)
Movement Disorders: Neurologic Principles and Practice (Second Edition)
, pp. 177-195
-
-
Marras, C.1
Tanner, C.2
-
4
-
-
0032497504
-
Parkinson's disease. First of two parts
-
Lang AE, Lozano AM. Parkinson's disease. First of two parts. N. Engl. J. Med. 339(15), 1044-1053 (1998).
-
(1998)
N. Engl. J. Med.
, vol.339
, Issue.15
, pp. 1044-1053
-
-
Lang, A.E.1
Lozano, A.M.2
-
5
-
-
19944432921
-
A common LRRK2 mutation in idiopathic Parkinson's disease
-
DOI 10.1016/S0140-6736(05)17830-1, PII S0140673605178301
-
Gilks WP, Abou-Sleiman PM, Gandhi S et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365(9457), 415-416 (2005). (Pubitemid 40179229)
-
(2005)
Lancet
, vol.365
, Issue.9457
, pp. 415-416
-
-
Gilks, W.P.1
Abou-Sleiman, P.M.2
Gandhi, S.3
Jain, S.4
Singleton, A.5
Lees, A.J.6
Shaw, K.7
Bhatia, K.P.8
Bonifati, V.9
Quinn, N.P.10
Lynch, J.11
Healy, D.G.12
Holton, J.L.13
Revesz, T.14
Wood, N.W.15
-
6
-
-
14944354884
-
Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years
-
DOI 10.1002/mds.20324
-
Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20(2), 190-199 (2005). •• Long-term outcomes in Parkinson's disease (PD). (Pubitemid 40361122)
-
(2005)
Movement Disorders
, vol.20
, Issue.2
, pp. 190-199
-
-
Hely, M.A.1
Morris, J.G.L.2
Reid, W.G.J.3
Trafficante, R.4
-
7
-
-
41149173996
-
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
-
Long-term morbidity in PD
-
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837-844 (2008). •• Long-term morbidity in PD.
-
(2008)
Mov. Disord.
, vol.23
, Issue.6
, pp. 837-844
-
-
Hely, M.A.1
Reid, W.G.2
Adena, M.A.3
Halliday, G.M.4
Morris, J.G.5
-
8
-
-
0034684139
-
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial
-
Parkinson Study Group
-
Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15), 1931-1938 (2000).
-
(2000)
JAMA
, vol.284
, Issue.15
, pp. 1931-1938
-
-
-
9
-
-
0034682308
-
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
-
DOI 10.1056/NEJM200005183422004
-
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000). (Pubitemid 30318272)
-
(2000)
New England Journal of Medicine
, vol.342
, Issue.20
, pp. 1484-1491
-
-
Rascol, O.1
Brooks, D.J.2
Korczyn, A.D.3
De Deyn, P.P.4
Clarke, C.E.5
Lang, A.E.6
-
10
-
-
0033809201
-
Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?
-
Molina JA, Sainz-Artiga MJ, Fraile A et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov. Disord. 15(5), 869-872 (2000).
-
(2000)
Mov. Disord.
, vol.15
, Issue.5
, pp. 869-872
-
-
Molina, J.A.1
Sainz-Artiga, M.J.2
Fraile, A.3
-
11
-
-
23844441981
-
Pathological gambling caused by drugs used to treat Parkinson disease
-
Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol. 62(9), 1377-1381 (2005).
-
(2005)
Arch. Neurol.
, vol.62
, Issue.9
, pp. 1377-1381
-
-
Dodd, M.L.1
Klos, K.J.2
Bower, J.H.3
Geda, Y.E.4
Josephs, K.A.5
Ahlskog, J.E.6
-
12
-
-
34447336974
-
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
-
Biglan KM, Holloway RG Jr, McDermott MP, Richard IH. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 69(2), 187-195 (2007).
-
(2007)
Neurology
, vol.69
, Issue.2
, pp. 187-195
-
-
Biglan, K.M.1
Holloway Jr., R.G.2
McDermott, M.P.3
Richard, I.H.4
-
13
-
-
0027935135
-
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase
-
DOI 10.1016/0306-3623(94)90082-5
-
Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25(5), 813-824 (1994). (Pubitemid 24295641)
-
(1994)
General Pharmacology
, vol.25
, Issue.5
, pp. 813-824
-
-
Kaakkola, S.1
Gordin, A.2
Mannisto, P.T.3
-
14
-
-
0346461762
-
Levodopa/carbidopa/entacapone (Stalevo)
-
Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 62(1 Suppl. 1), S64-S71 (2004).
-
(2004)
Neurology
, vol.62
, Issue.1 SUPPL. 1
-
-
Hauser, R.A.1
-
15
-
-
0027492354
-
Effects of catechol-O-methyltransferase inhibitors and L-3,4- Dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum
-
DOI 10.1111/j.1471-4159.1993.tb05831.x
-
Kaakkola S, Wurtman RJ. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J. Neurochem. 60(1), 137-144 (1993). (Pubitemid 23006711)
-
(1993)
Journal of Neurochemistry
, vol.60
, Issue.1
, pp. 137-144
-
-
Kaakkola, S.1
Wurtman, R.J.2
-
16
-
-
0027223850
-
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa
-
Guttman M, Leger G, Reches A et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord. 8(3), 298-304 (1993). (Pubitemid 23212538)
-
(1993)
Movement Disorders
, vol.8
, Issue.3
, pp. 298-304
-
-
Guttman, M.1
Leger, G.2
Reches, A.3
Evans, A.4
Kuwabara, H.5
Cedarbaum, J.M.6
Gjedde, A.7
-
17
-
-
0027522199
-
Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats
-
DOI 10.1016/0014-2999(93)90623-P
-
Tornwall M, Mannisto PT. Effects of three types of catechol O-methylation inhibitors on l-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur. J. Pharmacol. 250(1), 77-84 (1993). (Pubitemid 23353062)
-
(1993)
European Journal of Pharmacology
, vol.250
, Issue.1
, pp. 77-84
-
-
Tornwall, M.1
Mannisto, P.T.2
-
18
-
-
0030668631
-
Entacapone enhances Levodopa-induced reversal of motor disability in MPTP-Treated common marmosets
-
DOI 10.1002/mds.870120616
-
Smith LA, Gordin A, Jenner P, Marsden CD. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov. Disord. 12(6), 935-945 (1997). (Pubitemid 27496771)
-
(1997)
Movement Disorders
, vol.12
, Issue.6
, pp. 935-945
-
-
Smith, L.A.1
Gordin, A.2
Jenner, P.3
Marsden, C.D.4
-
19
-
-
0028078890
-
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
-
Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44(1), 77-80 (1994). (Pubitemid 24029433)
-
(1994)
Neurology
, vol.44
, Issue.1
, pp. 77-80
-
-
Kaakkola, S.1
Teravainen, H.2
Ahtila, S.3
Rita, H.4
Gordin, A.5
-
20
-
-
0026688379
-
Effects of COMT inhibitors on striatal dopamine metabolism: A microdialysis study
-
Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 587(2), 241-249 (1992).
-
(1992)
Brain Res.
, vol.587
, Issue.2
, pp. 241-249
-
-
Kaakkola, S.1
Wurtman, R.J.2
-
21
-
-
0026671534
-
Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone
-
Nissinen E, Linden IB, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 346(3), 262-266 (1992).
-
(1992)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.346
, Issue.3
, pp. 262-266
-
-
Nissinen, E.1
Linden, I.B.2
Schultz, E.3
Pohto, P.4
-
22
-
-
18144376227
-
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates
-
DOI 10.1002/mds.20317
-
Smith LA, Jackson MJ, Al-Barghouthy G et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. 20(3), 306-314 (2005). •• Support for early entacapone treatment. (Pubitemid 40613291)
-
(2005)
Movement Disorders
, vol.20
, Issue.3
, pp. 306-314
-
-
Smith, L.A.1
Jackson, M.J.2
Al-Barghouthy, G.3
Rose, S.4
Kuoppamaki, M.5
Olanow, W.6
Jenner, P.7
-
23
-
-
34648815104
-
Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease
-
DOI 10.1007/s00415-007-4007-9
-
Gordin A, Brooks D. Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. J. Neurol. 254(Suppl. 4), IV37-IV48 (2007). (Pubitemid 47457655)
-
(2007)
Journal of Neurology
, vol.254
, Issue.SUPPL. 4
-
-
Gordin, A.1
Brooks, D.J.2
-
24
-
-
70449228544
-
Enzymatic O-methylation of epinephrine and other catechols
-
Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233, 702-705 (1958).
-
(1958)
J. Biol. Chem.
, vol.233
, pp. 702-705
-
-
Axelrod, J.1
Tomchick, R.2
-
25
-
-
0016829492
-
Catechol-Omethyl transferase: Pharmacological aspects and physiological role
-
Guldberg HC, Marsden CA. Catechol-Omethyl transferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27(2), 135-206 (1975).
-
(1975)
Pharmacol. Rev.
, vol.27
, Issue.2
, pp. 135-206
-
-
Guldberg, H.C.1
Marsden, C.A.2
-
26
-
-
1842338351
-
Monoamine methyltransferases
-
Boulton AA BG, Yu PH (Eds). The Humana Press, Clifton, NJ, USA
-
Park D. Monoamine methyltransferases. In: Neuromethods 5: Neurotransmitter Enzymes (3rd Edition). Boulton AA BG, Yu PH (Eds). The Humana Press, Clifton, NJ, USA (1986).
-
(1986)
Neuromethods 5: Neurotransmitter Enzymes (3rd Edition)
-
-
Park, D.1
-
27
-
-
67651025302
-
-
The Humana Press, Clifton, NJ, USA
-
Boulton AA, Baker GB, Yu PH. Neurotransmitter enzymes. The Humana Press, Clifton, NJ, USA (1986).
-
(1986)
Neurotransmitter Enzymes
-
-
Boulton, A.A.1
Baker, G.B.2
Yu, P.H.3
-
28
-
-
0025119634
-
Human liver catechol-O-methyltransferase pharmacogenetics
-
Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48(4), 381-389 (1990).
-
(1990)
Clin. Pharmacol. Ther.
, vol.48
, Issue.4
, pp. 381-389
-
-
Boudikova, B.1
Szumlanski, C.2
Maidak, B.3
Weinshilboum, R.4
-
29
-
-
0037176816
-
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease
-
Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58(4), 564-567 (2002).
-
(2002)
Neurology
, vol.58
, Issue.4
, pp. 564-567
-
-
Lee, M.S.1
Kim, H.S.2
Cho, E.K.3
Lim, J.H.4
Rinne, J.O.5
-
30
-
-
0021355653
-
Pharmacokinetics of levodopa
-
Classic paper on levodopa pharmacokinetics
-
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 7(1), 35-49 (1984). • Classic paper on levodopa pharmacokinetics.
-
(1984)
Clin. Neuropharmacol.
, vol.7
, Issue.1
, pp. 35-49
-
-
Nutt, J.G.1
Fellman, J.H.2
-
31
-
-
0023404750
-
Clinical pharmacokinetics of anti-parkinsonian drugs
-
Classic paper of pharmacokinetics in PD
-
Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmacokinet. 13(3), 141-178 (1987). •• Classic paper of pharmacokinetics in PD.
-
(1987)
Clin. Pharmacokinet.
, vol.13
, Issue.3
, pp. 141-178
-
-
Cedarbaum, J.M.1
-
32
-
-
0017197009
-
Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of parkinsonism
-
Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 11(5), 329-377 (1976).
-
(1976)
Drugs
, vol.11
, Issue.5
, pp. 329-377
-
-
Pinder, R.M.1
Brogden, R.N.2
Sawyer, P.R.3
Speight, T.M.4
Avery, G.S.5
-
33
-
-
7944236868
-
Clinical advantages of COMT inhibition with entacapone - A review
-
DOI 10.1007/s00702-004-0190-3, Parkinson's Research in Progress
-
Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone - a review. J. Neural Transm. 111(10-11), 1343-1363 (2004). (Pubitemid 39468395)
-
(2004)
Journal of Neural Transmission
, vol.111
, Issue.10-11
, pp. 1343-1363
-
-
Gordin, A.1
Kaakkola, S.2
Teravainen, H.3
-
34
-
-
0026724717
-
3-O-methyldopa administration does not alter fluorodopa transport into the brain
-
Guttman M, Leger G, Cedarbaum JM et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann. Neurol. 31(6), 638-643 (1992).
-
(1992)
Ann. Neurol.
, vol.31
, Issue.6
, pp. 638-643
-
-
Guttman, M.1
Leger, G.2
Cedarbaum, J.M.3
-
35
-
-
0023265840
-
3-O-Methyldopa and the response to levodopa in Parkinson's disease
-
DOI 10.1002/ana.410210610
-
Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann. Neurol. 21(6), 584-588 (1987). (Pubitemid 17081194)
-
(1987)
Annals of Neurology
, vol.21
, Issue.6
, pp. 584-588
-
-
Nutt, J.G.1
Woodward, W.R.2
Gancher, S.T.3
Merrick, D.4
-
36
-
-
0028810238
-
Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices
-
Chang WY, Webster RA. Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices. Br. J. Pharmacol. 116(6), 2637-2640 (1995).
-
(1995)
Br. J. Pharmacol.
, vol.116
, Issue.6
, pp. 2637-2640
-
-
Chang, W.Y.1
Webster, R.A.2
-
37
-
-
0025911879
-
Reduction of circulating 3-O-methyldopa by inhibition of catechol-Omethyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease
-
Cedarbaum JM, Leger G, Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-Omethyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 14(4), 330-342 (1991).
-
(1991)
Clin. Neuropharmacol.
, vol.14
, Issue.4
, pp. 330-342
-
-
Cedarbaum, J.M.1
Leger, G.2
Guttman, M.3
-
38
-
-
0034968037
-
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
-
DOI 10.1097/00002826-200105000-00006
-
Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson's disease. Clin. Neuropharmacol. 24(3), 150-157 (2001). (Pubitemid 32549990)
-
(2001)
Clinical Neuropharmacology
, vol.24
, Issue.3
, pp. 150-157
-
-
Heikkinen, H.1
Nutt, J.G.2
Lewitt, P.A.3
Koller, W.C.4
Gordin, A.5
-
39
-
-
0027514196
-
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
-
Keranen T, Gordin A, Harjola VP et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 16(2), 145-156 (1993). (Pubitemid 23090692)
-
(1993)
Clinical Neuropharmacology
, vol.16
, Issue.2
, pp. 145-156
-
-
Keranen, T.1
Gordin, A.2
Harjola, V.-P.3
Karlsson, M.4
Korpela, K.5
Pentikainen, P.J.6
Rita, H.7
Seppala, L.8
Wikberg, T.9
-
40
-
-
21544474680
-
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with sinemet CR
-
DOI 10.1097/01.wnf.0000166393.33781.87
-
Paija O, Laine K, Kultalahti ER et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin. Neuropharmacol. 28(3), 115-119 (2005). (Pubitemid 40923409)
-
(2005)
Clinical Neuropharmacology
, vol.28
, Issue.3
, pp. 115-119
-
-
Paija, O.1
Laine, K.2
Kultalahti, E.-R.3
Leinonen, M.4
Huupponen, R.5
Gordin, A.6
Reinikainen, K.7
-
41
-
-
0038287034
-
Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
-
Comprehensive review of the properties of catechol-O-methyltransferase (COMT)
-
Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51(4), 593-628 (1999). •• Comprehensive review of the properties of catechol-O-methyltransferase (COMT).
-
(1999)
Pharmacol. Rev.
, vol.51
, Issue.4
, pp. 593-628
-
-
Mannisto, P.T.1
Kaakkola, S.2
-
42
-
-
0028203007
-
Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
-
Keranen T, Gordin A, Karlsson M et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 46(2), 151-157 (1994). (Pubitemid 24101334)
-
(1994)
European Journal of Clinical Pharmacology
, vol.46
, Issue.2
, pp. 151-157
-
-
Keranen, T.1
Gordin, A.2
Karlsson, M.3
Korpela, K.4
Pentikainen, P.J.5
Rita, H.6
Schultz, E.7
Seppala, L.8
Wikberg, T.9
-
43
-
-
0027417592
-
Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans
-
Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 21(1), 81-92 (1993). (Pubitemid 23052226)
-
(1993)
Drug Metabolism and Disposition
, vol.21
, Issue.1
, pp. 81-92
-
-
Wikberg, T.1
Vuorela, A.2
Ottoila, P.3
Taskinen, J.4
-
44
-
-
0034465426
-
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man -A study using a stable isotope technique
-
DOI 10.1007/s002280000244
-
Heikkinen H, Saraheimo M, Antila S, Ottoila P, Pentikainen PJ. Pharmacokinetics of entacapone, a peripherally acting catechol-O- methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur. J. Clin. Pharmacol. 56(11), 821-826 (2001). (Pubitemid 33788554)
-
(2001)
European Journal of Clinical Pharmacology
, vol.56
, Issue.11
, pp. 821-826
-
-
Heikkinen, H.1
Saraheimo, M.2
Antila, S.3
Ottoila, P.4
Pentikainen, P.J.5
-
45
-
-
0026570182
-
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat
-
Early discussion of potential COMT inhibitors and their possible use in PD
-
Mannisto PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105(3), 569-574 (1992). • Early discussion of potential COMT inhibitors and their possible use in PD.
-
(1992)
Br. J. Pharmacol.
, vol.105
, Issue.3
, pp. 569-574
-
-
Mannisto, P.T.1
Tuomainen, P.2
Tuominen, R.K.3
-
46
-
-
0032785423
-
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition
-
DOI 10.1007/s002280050657
-
Rouru J, Gordin A, Huupponen R et al. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur. J. Clin. Pharmacol. 55(6), 461-467 (1999). (Pubitemid 29399659)
-
(1999)
European Journal of Clinical Pharmacology
, vol.55
, Issue.6
, pp. 461-467
-
-
Rouru, J.1
Gordin, A.2
Huupponen, R.3
Huhtala, S.4
Savontaus, E.5
Korpela, K.6
Reinikainen, K.7
Scheinin, M.8
-
47
-
-
0024511327
-
New selective COMT inhibitors: Useful adjuncts for Parkingson's disease?
-
DOI 10.1016/0165-6147(89)90075-8
-
Mannisto PT, Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol. Sci. 10(2), 54-56 (1989). (Pubitemid 19059710)
-
(1989)
Trends in Pharmacological Sciences
, vol.10
, Issue.2
, pp. 54-56
-
-
Mannisto, P.T.1
Kaakkola, S.2
-
48
-
-
0028286186
-
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
-
Nutt JG, Woodward WR, Beckner RM et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44(5), 913-919 (1994).
-
(1994)
Neurology
, vol.44
, Issue.5
, pp. 913-919
-
-
Nutt, J.G.1
Woodward, W.R.2
Beckner, R.M.3
-
49
-
-
0036431658
-
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose
-
DOI 10.1046/j.1365-2125.2002.01654.x
-
Heikkinen H, Varhe A, Laine T et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L -dopa/carbidopa dose. Br. J. Clin. Pharmacol. 54(4), 363-371 (2002). (Pubitemid 35334948)
-
(2002)
British Journal of Clinical Pharmacology
, vol.54
, Issue.4
, pp. 363-371
-
-
Heikkinen, H.1
Varhe, A.2
Laine, T.3
Puttonen, J.4
Kela, M.5
Kaakkola, S.6
Reinikainen, K.7
-
50
-
-
0034058782
-
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
-
DOI 10.1136/jnnp.68.5.589
-
Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 68(5), 589-594 (2000). (Pubitemid 30248823)
-
(2000)
Journal of Neurology Neurosurgery and Psychiatry
, vol.68
, Issue.5
, pp. 589-594
-
-
Piccini, P.1
Brooks, D.J.2
Korpela, K.3
Pavese, N.4
Karlsson, M.5
Gordin, A.6
-
51
-
-
39149094302
-
Bimodal administration of entacapone in Parkinson's disease patients improves motor control
-
DOI 10.1111/j.1468-1331.2007.02043.x
-
Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J. Neurol. 15(3), 268-273 (2008). (Pubitemid 351257918)
-
(2008)
European Journal of Neurology
, vol.15
, Issue.3
, pp. 268-273
-
-
Bet, L.1
Bareggi, S.R.2
Pacei, F.3
Bondiolotti, G.4
Meola, G.5
Schapira, A.H.V.6
-
52
-
-
0028891614
-
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers
-
Ahtila S, Kaakkola S, Gordin A et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol. 18(1), 46-57 (1995).
-
(1995)
Clin. Neuropharmacol.
, vol.18
, Issue.1
, pp. 46-57
-
-
Ahtila, S.1
Kaakkola, S.2
Gordin, A.3
-
53
-
-
0027436117
-
The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise
-
Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keranen T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br. J. Clin. Pharmacol. 36(5), 451-456 (1993). (Pubitemid 23344155)
-
(1993)
British Journal of Clinical Pharmacology
, vol.36
, Issue.5
, pp. 451-456
-
-
Sundberg, S.1
Scheinin, M.2
Illi, A.3
Akkila, J.4
Gordin, A.5
Keranen, T.6
-
54
-
-
0028137620
-
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
-
Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57(2), 186-189 (1994). (Pubitemid 24050458)
-
(1994)
Journal of Neurology Neurosurgery and Psychiatry
, vol.57
, Issue.2
, pp. 186-189
-
-
Merello, M.1
Lees, A.J.2
Webster, R.3
Bovingdon, M.4
Gordin, A.5
-
55
-
-
0027445460
-
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
-
DOI 10.1007/BF00315512
-
Myllyla VV, Sotaniemi KA, Illi A, Suominen K, Keranen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 45(5), 419-423 (1993). (Pubitemid 23361940)
-
(1993)
European Journal of Clinical Pharmacology
, vol.45
, Issue.5
, pp. 419-423
-
-
Myllyla, V.V.1
Sotaniemi, K.A.2
Illi, A.3
Suominen, K.4
Keranen, T.5
-
56
-
-
0030042649
-
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
-
Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J. Neurol. Neurosurg. Psychiatry 60(1), 36-40 (1996).
-
(1996)
J. Neurol. Neurosurg. Psychiatry
, vol.60
, Issue.1
, pp. 36-40
-
-
Ruottinen, H.M.1
Rinne, U.K.2
-
57
-
-
0029895288
-
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease
-
Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19(4), 283-296 (1996).
-
(1996)
Clin. Neuropharmacol.
, vol.19
, Issue.4
, pp. 283-296
-
-
Ruottinen, H.M.1
Rinne, U.K.2
-
58
-
-
0030778373
-
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
-
Parkinson Study Group
-
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann. Neurol. 42(5), 747-755 (1997).
-
(1997)
Ann. Neurol.
, vol.42
, Issue.5
, pp. 747-755
-
-
-
59
-
-
0031773064
-
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
-
Rinne UK, Larsen JP, Siden A, Worm- Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5), 1309-1314 (1998). (Pubitemid 28520549)
-
(1998)
Neurology
, vol.51
, Issue.5
, pp. 1309-1314
-
-
Rinne, U.K.1
Larsen, J.P.2
Siden, A.3
Worm-Petersen, J.4
-
60
-
-
0036113588
-
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo controlled double blind study in Germany and Austria (Celomen study)
-
DOI 10.1034/j.1600-0404.2002.1o174.x
-
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. 105(4), 245-255 (2002). (Pubitemid 34407226)
-
(2002)
Acta Neurologica Scandinavica
, vol.105
, Issue.4
, pp. 245-255
-
-
Poewe, W.H.1
Deuschl, G.2
Gordin, A.3
Kultalahti, E.-R.4
Leinonen, M.5
-
61
-
-
0041704637
-
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study
-
DOI 10.1136/jnnp.74.8.1071
-
Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry 74(8), 1071-1079 (2003). (Pubitemid 36936383)
-
(2003)
Journal of Neurology Neurosurgery and Psychiatry
, vol.74
, Issue.8
, pp. 1071-1079
-
-
Brooks, D.J.1
Sagar, H.2
-
62
-
-
44949107374
-
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease
-
Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J. Neural Transm. 115(6), 843-849 (2008).
-
(2008)
J. Neural Transm.
, vol.115
, Issue.6
, pp. 843-849
-
-
Brooks, D.J.1
Leinonen, M.2
Kuoppamaki, M.3
Nissinen, H.4
-
63
-
-
34748926549
-
Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off
-
DOI 10.1002/mds.21473
-
Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of Entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov. Disord. 22(11), 1550-1555 (2007). • Direct comparative trial of entacapone versus a dopamine agonist. (Pubitemid 47477914)
-
(2007)
Movement Disorders
, vol.22
, Issue.11
, pp. 1550-1555
-
-
Deuschl, G.1
Vaitkus, A.2
Fox, G.-C.3
Roscher, T.4
Schremmer, D.5
Gordin, A.6
-
64
-
-
0032962836
-
Health-related quality-of-life measurement in patients with Parkinson's disease
-
DOI 10.2165/00019053-199915020-00004
-
Jenkinson C, Fitzpatrick R, Peto V. Health-related quality-of-life measurement in patients with Parkinson's disease. Pharmacoeconomics 15(2), 157-165 (1999). (Pubitemid 29093258)
-
(1999)
PharmacoEconomics
, vol.15
, Issue.2
, pp. 157-165
-
-
Jenkinson, C.1
Fitzpatrick, R.2
Peto, V.3
-
65
-
-
33846454748
-
Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): Results from America, Canada, Japan, Italy and Spain
-
DOI 10.1016/j.parkreldis.2006.06.006, PII S1353802006001465
-
Jenkinson C, Fitzpatrick R. Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): results from America, Canada, Japan, Italy and Spain. Parkinsonism Relat. Disord. 13(1), 22-28 (2007). (Pubitemid 46149444)
-
(2007)
Parkinsonism and Related Disorders
, vol.13
, Issue.1
, pp. 22-28
-
-
Jenkinson, C.1
Fitzpatrick, R.2
-
66
-
-
0035102930
-
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open, multicenter study
-
DOI 10.1159/000052104
-
Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur. Neurol. 45(2), 111-118 (2001). (Pubitemid 32215799)
-
(2001)
European Neurology
, vol.45
, Issue.2
, pp. 111-118
-
-
Durif, F.1
Devaux, I.2
Pere, J.-J.3
Delumeau, J.-C.4
Bourdeix, I.5
-
67
-
-
12744272177
-
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations
-
Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol. Scand. 111(1), 21-28 (2005).
-
(2005)
Acta Neurol. Scand.
, vol.111
, Issue.1
, pp. 21-28
-
-
Reichmann, H.1
Boas, J.2
Macmahon, D.3
Myllyla, V.4
Hakala, A.5
Reinikainen, K.6
-
68
-
-
3843063551
-
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study
-
Onofrj M, Thomas A, Vingerhoets F et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J. Neural Transm. 111(8), 1053-1063 (2004). (Pubitemid 39037126)
-
(2004)
Journal of Neural Transmission
, vol.111
, Issue.8
, pp. 1053-1063
-
-
Onofrj, M.1
Thomas, A.2
Vingerhoets, F.3
Martin, W.4
Gimenez-Roldan, S.5
Azulay, J.-P.6
Bernhard, G.7
Schmidt, W.8
Markabi, S.9
-
69
-
-
0141851875
-
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: An international, multicentre, open-label study
-
DOI 10.1016/S0278-5846(03)00156-8
-
Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(6), 963-971 (2003). (Pubitemid 37141384)
-
(2003)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.27
, Issue.6
, pp. 963-971
-
-
Gershanik, O.1
Emre, M.2
Bernhard, G.3
Sauer, D.4
-
70
-
-
5344247928
-
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
-
DOI 10.1001/archneur.61.10.1563
-
Olanow CW, Kieburtz K, Stern M et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch. Neurol. 61(10), 1563-1568 (2004). (Pubitemid 39350267)
-
(2004)
Archives of Neurology
, vol.61
, Issue.10
, pp. 1563-1568
-
-
Olanow, C.W.1
Kieburtz, K.2
Stern, M.3
Watts, R.4
Langston, J.W.5
Guarnieri, M.6
Hubble, J.7
-
71
-
-
33847762823
-
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: The effects of an early therapeutic intervention
-
DOI 10.1111/j.1468-1331.2006.01635.x
-
Grandas F, Hernandez B. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. Eur J. Neurol. 14(3), 282-289 (2007). (Pubitemid 46384864)
-
(2007)
European Journal of Neurology
, vol.14
, Issue.3
, pp. 282-289
-
-
Grandas, F.1
Hernandez, B.2
-
72
-
-
39149128281
-
Should levodopa dose be reduced when switched to stalevo?
-
DOI 10.1111/j.1468-1331.2007.02047.x
-
Linazasoro G, Kulisevsky J, Hernandez B. Should levodopa dose be reduced when switched to stalevo? Eur J. Neurol. 15(3), 257-261 (2008). (Pubitemid 351257922)
-
(2008)
European Journal of Neurology
, vol.15
, Issue.3
, pp. 257-261
-
-
Linazasoro, G.1
Kulisevsky, J.2
Hernandez, B.3
-
73
-
-
61449119974
-
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
-
Recent quality of life study in early PD
-
Fung VS, Herawati L, Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov. Disord. 24(1), 25-31 (2009). • Recent quality of life study in early PD.
-
(2009)
Mov. Disord.
, vol.24
, Issue.1
, pp. 25-31
-
-
Fung, V.S.1
Herawati, L.2
Wan, Y.3
-
74
-
-
13144307100
-
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off
-
DOI 10.1007/s00702-004-0184-1
-
Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J. Neural Transm. 112(2), 221-230 (2005). (Pubitemid 40179116)
-
(2005)
Journal of Neural Transmission
, vol.112
, Issue.2
, pp. 221-230
-
-
Koller, W.1
Guarnieri, M.2
Hubble, J.3
Rabinowicz, A.L.4
Silver, D.5
-
75
-
-
22744453722
-
Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
-
DOI 10.1159/000086479
-
Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur. Neurol. 53(4), 197-202 (2005). • Comparison of combination tablet Stalevo® to carbidopa/levidopa plus entacapone. (Pubitemid 41404749)
-
(2005)
European Neurology
, vol.53
, Issue.4
, pp. 197-202
-
-
Brooks, D.J.1
Agid, Y.2
Eggert, K.3
Widner, H.4
Ostergaard, K.5
Holopainen, A.6
-
76
-
-
33746921227
-
Patient satisfaction with switching to Stalevo: An open-label evaluation in PD patients experiencing wearing-off (Simcom Study)
-
DOI 10.1111/j.1600-0404.2006.00703.x
-
Myllyla V, Haapaniemi T, Kaakkola S et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol. Scand. 114(3), 181-186 (2006). (Pubitemid 44185911)
-
(2006)
Acta Neurologica Scandinavica
, vol.114
, Issue.3
, pp. 181-186
-
-
Myllyla, V.1
Haapaniemi, T.2
Kaakkola, S.3
Kinnunen, E.4
Hartikainen, P.5
Nuutinen, J.6
Rissanen, A.7
Kuopio, A.M.8
Jolma, T.9
Satomaa, O.10
Heikkinen, H.11
-
77
-
-
36148968428
-
The administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates
-
DOI 10.1016/j.expneurol.2007.05.002, PII S001448860700194X
-
Zubair M, Jackson MJ, Tayarani-Binazir K et al. The administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Exp. Neurol. 208(2), 177-184 (2007). •• Support for early entacapone treatment. (Pubitemid 350110430)
-
(2007)
Experimental Neurology
, vol.208
, Issue.2
, pp. 177-184
-
-
Zubair, M.1
Jackson, M.J.2
Tayarani-Binazir, K.3
Stockwell, K.A.4
Smith, L.A.5
Rose, S.6
Olanow, W.7
Jenner, P.8
-
78
-
-
67651062724
-
Evaluation of the Efficacy of Stalevo in de novo Parkinson's disease
-
Hauser R. First Step: Evaluation of the Efficacy of Stalevo in de novo Parkinson's disease. Eur J. Neurol. 13(Suppl. 2), 94 (2006).
-
(2006)
Eur J. Neurol.
, vol.13
, Issue.SUPPL. 2
, pp. 94
-
-
Hauser, R.1
Step, F.2
-
79
-
-
67651034799
-
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
-
Large double-blind trial with primary Unified PD Rating Scale end points
-
Hauser R, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov. Disord. 24(4), 541-550 (2009). •• Large double-blind trial with primary Unified PD Rating Scale end points.
-
(2009)
Mov. Disord.
, vol.24
, Issue.4
, pp. 541-550
-
-
Hauser, R.1
Panisset, M.2
Abbruzzese, G.3
Mancione, L.4
Dronamraju, N.5
Kakarieka, A.6
-
80
-
-
0037338132
-
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease
-
DOI 10.1046/j.1468-1331.2003.00559.x
-
Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J. Neurol. 10(2), 137-146 (2003). • Long-term safety in entacapone treatment. (Pubitemid 36308207)
-
(2003)
European Journal of Neurology
, vol.10
, Issue.2
, pp. 137-146
-
-
Larsen, J.P.1
Worm-Petersen, J.2
Siden, A.3
Gordin, A.4
Reinikainen, K.5
Leinonen, M.6
-
81
-
-
0035130228
-
Twelve-month safety of entacapone in patients with Parkinson's disease
-
DOI 10.1046/j.1468-1331.2001.00168.x
-
Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur. J. Neurol. 8(1), 53-60 (2001). (Pubitemid 32154574)
-
(2001)
European Journal of Neurology
, vol.8
, Issue.1
, pp. 53-60
-
-
Myllyla, V.V.1
Kultalahti, E.-R.2
Haapaniemi, H.3
Leinonen, M.4
Aho, K.5
Alhainen, K.6
Havanka, H.7
Herrala, L.8
Ilmavirta, M.9
Jolma, T.10
Junes, M.11
Kaakkola, S.12
Keranen, T.13
Kilpelainen, H.14
Kinnunen, E.15
Mannila, S.16
Mulari, A.17
Makinen, T.18
Numminen, H.19
Nuutinen, J.20
Pammo, O.21
Peltola, J.22
Pieninkeroinen, I.23
Pilke, A.24
Rautakorpi, I.25
Rissanen, A.26
Saarinen, A.27
Saksa, M.28
Satomaa, O.29
Seppa, J.-M.30
Siirtola, T.31
Soikkeli, R.32
Solismaa, M.33
Sotaniemi, K.34
Taalas, I.J.35
Teravainen, E.36
Teravainen, H.37
Tuisku, S.38
Valpas, J.39
Reinikainen, K.40
Gordin, A.41
more..
-
82
-
-
0036058786
-
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States
-
Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 20(9), 617-628 (2002). (Pubitemid 34898997)
-
(2002)
PharmacoEconomics
, vol.20
, Issue.9
, pp. 617-628
-
-
Palmer, C.S.1
Nuijten, M.J.C.2
Schmier, J.K.3
Subedi, P.4
Snyder, E.H.5
-
83
-
-
0034879268
-
Cost-effectiveness analysis of entacapone in Parkinson's disease: A Markov process analysis
-
Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 4(4), 316-328 (2001). (Pubitemid 32756816)
-
(2001)
Value in Health
, vol.4
, Issue.4
, pp. 316-328
-
-
Nuijten, M.J.C.1
Van Iperen, P.2
Palmer, C.3
Van Hilten, B.J.4
Snyder, E.5
-
84
-
-
33846438583
-
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
-
DOI 10.1002/mds.21123
-
Korchounov A, Bogomazov G. Employment, medical absenteeism, and disability perception in Parkinson's disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. Mov. Disord. 21(12), 2220-2224 (2006). (Pubitemid 46140443)
-
(2006)
Movement Disorders
, vol.21
, Issue.12
, pp. 2220-2224
-
-
Korchounov, A.1
Bogomazov, G.2
-
85
-
-
67651037675
-
-
Transdermal delivery of a levodopa prodrug: a pilot clinical trial. (Poster 592)
-
Kushnir M, Yaar A, Reichman A, Heldman E. Transdermal delivery of a levodopa prodrug: a pilot clinical trial. Program of the 12th International Congress of Parkinson's Disease and Movement Disorders. Chicago, IL, USA, 22-26 June 2008 (Poster 592).
-
Program of the 12th International Congress of Parkinson's Disease and Movement Disorders. Chicago, IL, USA, 22-26 June 2008
-
-
Kushnir, M.1
Yaar, A.2
Reichman, A.3
Heldman, E.4
-
86
-
-
33750725397
-
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease
-
DOI 10.1586/14737175.6.10.1403
-
Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev. Neurother. 6, 1403-1411 (2006). (Pubitemid 44696265)
-
(2006)
Expert Review of Neurotherapeutics
, vol.6
, Issue.10
, pp. 1403-1411
-
-
Nyholm, D.1
-
87
-
-
37849023418
-
New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer
-
Goole J, Deleuze P, Vanderbist F et al. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur. J. Biopharm. 68, 310-318 (2008).
-
(2008)
Eur. J. Biopharm.
, vol.68
, pp. 310-318
-
-
Goole, J.1
Deleuze, P.2
Vanderbist, F.3
|